The large, two-story light gray canister on three legs takes up a corner of the Nuclear Magnetic Resonance (NMR) lab in the basement of a modern research building on the University of Maryland campus in Baltimore.
MedImmune, the global biologics research and development arm of pharmaceutical giant AstraZeneca, and the University of Maryland, Baltimore (UMB) have entered into a five-year, $6 million collaboration to drive novel bioscience research in Maryland.